TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.
Read original at benzingaStocks · News reference
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 5:14 PM
- Checked
- Aug 20, 2026, 5:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?
Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biotech stock to a new 52-week high.
Read original at benzingaIovance Biotherapeutics shares are trading higher after UBS maintained its Neutral rating on the stock and raised its price target from $4 to $7.
Read original at benzingaSMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-researchModerna Borrows $2 Billion To Expand Oncology Business
Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.
Read original at benzingaEXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.
Read original at benzinga